Cargando…
Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML
Therapy-related and more specifically radiotherapy-associated acute myeloid leukaemia (AML) is a well-recognized potential complication of cytotoxic therapy for the treatment of a primary cancer. The CBA mouse model is used to study radiation leukaemogenesis mechanisms with Sfpi1/PU.1 deletion and p...
Autores principales: | O’Brien, Gráinne, Cruz-Garcia, Lourdes, Zyla, Joanna, Brown, Natalie, Finnon, Rosemary, Polanska, Joanna, Badie, Christophe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422620/ https://www.ncbi.nlm.nih.gov/pubmed/31646336 http://dx.doi.org/10.1093/carcin/bgz175 |
Ejemplares similares
-
Transcriptomic and proteomic analysis of mouse radiation-induced acute myeloid leukaemia (AML)
por: Badie, Christophe, et al.
Publicado: (2016) -
DRP1 promotes lactate utilization in KRAS‐mutant non‐small‐cell lung cancer cells
por: Hu, Mangze, et al.
Publicado: (2020) -
Tracking preleukemic cells in vivo to reveal the sequence of molecular events in radiation leukemogenesis
por: Verbiest, Tom, et al.
Publicado: (2018) -
PU.1 downregulation in murine radiation-induced acute myeloid leukaemia (AML): from molecular mechanism to human AML
por: Verbiest, Tom, et al.
Publicado: (2015) -
Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein
por: Laurson, Joanna, et al.
Publicado: (2010)